BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LBT-3627 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LBT-3627\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06466525-1676@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:LBT-3627: Phase 1 readout est. (NCT06466525)
DESCRIPTION:LBT-3627\, phase 1\, Parkinson's Disease.\nStudy: A Two-Part Si
 ngle and Multiple Ascending Dose Trial of the Safety\, Tolerability\, Phar
 macokinetics\, and Pharmacodynamics of LBT-3627 in Healthy Participants an
 d in Participants With Parkinson's Disease.\nEstimated primary completion:
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lbt-3
 627#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06466525
URL:https://assetmemo.bio/drug/lbt-3627#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
